Periodic Reporting for period 1 - Respiratory Analyzer (Validation of calibrated RIP (respiratory inductive plethysmography) based biomarker for diagnosis of SDB (sleep-disordered breathing) and the identification of an accessible screening solution)
Berichtszeitraum: 2015-06-01 bis 2015-10-31
The marketing effort related to the feasibility study involved visiting conferences and exhibitions, and contacting customers worldwide during the study. The results generated in the Feasibility study inspire further clinical validation of the Biomarker.
The market research clearly identified a need in the market for the Biomarker and possible applications of the Biomarker extend far beyond sleep science. The market is waiting for a solution that can be applied to diagnose SDB both to be able to diagnose patients who suffer from SDB and are not diagnosed with current methods, and to diagnose the underlying cause of SDB in patients and target treatment to the cause. The Biomarker needs to be clinically validated to be accepted as a basis for diagnostics.
To fully exploit the market opportunity two main tasks need to be worked on:
1) Nox Medical has applied for Phase II in the SME Instrument to finance clinical validation of the Biomarker. This will allow Nox Medical to augment current sleep diagnostics and allow sleep specialists to enhance their diagnostics capabilities to diagnose patients who cannot be diagnosed with current methods.
2) A development of a novel sleep diagnostics device and service that allows other medical professionals than sleep specialists to use sleep diagnostics as a routine diagnostics tool.
The development of this solution will mark the start of a revolution in sleep diagnostics devices.